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The observed increase in cancer led to a continuous rise in anticancer drug preparations in Hospital Centres. 
The quality and security of these preparations are essential to ensure the efficacy and to limit the risk of iatro-
genic toxicity. Several methods have been described to secure the process of preparation (i.e. non-analytical 
methods for the control during the fabrication; analytical methods for the final product evaluation). These different 
methods have been presented in many studies, in particular in descriptive studies, but in practice, selecting a 
method is difficult and related to needs and hospital priorities. Therefore, we decided to conduct this present 
review focused on various existing methods allowing enhancement in security of anti-cancer drugs preparation 
process. A proactive hazard analysis method was applied, considering preparation and control steps, to discuss 
the choice of a method in terms of quality and security and to identify potential risks of failure. The results show 
that none method is perfect. Methods with the lowest criticality score are the robotization closely followed by 
Drugcam® in the case of re-labelling of all containers. According to these elements a University Hospital Centre 
could consider these risk indexesimplementing control methods.
1. Introduction
Anticancer drugs are involved in complex and individualized 
treatment protocols, with the emergence of personalized medicine 
in recent years (Butts et al. 2013; INCa 2012; Institute of Mede-
cine 2017). Because of their narrow therapeutic index (NTI) and 
iatrogenic risk, anticancer agents are considered as “high alert 
medications” (Institute for Safe Medication Practices 2017; Carrez 
et  al. 2014). The anticancer drugs production process carries a 
particularly high degree of risk and medication error in oncology 
and can have serious impacts on the health of patients (Butts et al. 
2013; Carrez et al. 2014; INCa 2012; Institute for Safe Medica-
tion Practices 2017; JORF n°0090 2011). Indeed, many studies 
confirmed that the risks of errors concern all dispensation stages 
process (prescription analysis, preparation, control, delivery and 
patient information) and also prescription and administration 
stages (Ashley et al. 2011; Bonan et al. 2009; Bonnabry et al. 2006; 
Cairns et al. 2016; Chia-Hui et al. 2012; Christine et al. 2011; Ciofi 
et al. 2013; Fyhr and Akslsson 2012; Kathleen et al. 2013; Limat 
et  al. 2001; Mattsson et  al. 2015; Pongudom and Chinthammitr 
2011; Ranchon et  al. 2011; Robinson et  al. 2006; Tournel et  al. 
2006; Ulas et  al. 2015; Van Tilburg et  al. 2006; Weingart et  al. 
2010). These studies highlight a complex process which involves 
several trades: physicians, pharmacists and nurses. Many teams 
mapped the entire process (Chia-Hui et al. 2012; Van Tilburg et al. 
2006; Bonan et al. 2009; Robinson et al. 2006; Ciofi et al. 2013), 
some studies targeted only prescription (Christine et al. 2011) or 
administration processes (Ashley et al. 2011) and others described 
the process until patient’s home (Kathleen et al. 2013; Bonnabry 
et al. 2006 ). A recent review compared non analytical and analyt-
ical methods but did not consider robotization in its original SWOT 
analysis (Bazin et al. 2015).
Actions made to secure the process of preparation of chemothera-
pies the last decade conducted to the preparation of these drugs in 
centralized reconstitution units. Thus, pharmacists can contribute 
to enhance security through the improvement of chemotherapy 
preparation process. Even though a system allowing the control of 
anticancer chemotherapy preparations is imposed, the analytical 
control is not obligatory even if it seems fundamental to ensure 
patient safety without neglecting the staff and its environment 
in terms of exposure, often described in the literature (MEWIP 
studies, Moretti et  al.2015, Petit et  al. 2017, Nussbaumer et  al. 
2011; Rekhadevi et al 2007; Sasaki et al 2016; Sessink et al. 2015; 
Sottani et  al. 2012). There are different chemotherapy produc-
tion or control methods, from simple visual control to robotized 
compounding. No method was clearly established as a gold stan-
dard (Bazin et al. 2015). The choice should take into account the 
needs and the financial possibilities of each institution. That is why 
this type of control and production method varies from one hospital 
to another. Thus, in order to make the whole process secure and to 
ensure the quality and safety of patient care, proactive hazard anal-
ysis method using Failure Mode Effect and Criticality Analysis 
(FMECA) or Functional Resonance Accident Model (FRAM) can 
be employed to identify potential chemotherapy process failures 
(JORF n°0090 2011). These methods are directed towards the 
analysis of each process, step by step, to identify and to assess 
potential vulnerabilities. Initially used in the industrial field and 
expanded in the health care area, these methods are nowadays 
widely used in risk management in medical oncology. To date, 
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no study has considered proactive risk analysis focused on the 
methods of anticancer preparation production and control process. 
The current study focused on various existing methods allowing 
security enhancement in chemotherapies preparation process and 
discussing the choice of a method in terms of quality and secu-
rity, using a proactive hazard analysis method in order to identify 
potential chemotherapies step process failures.
2. Methods for the control of chemotherapy prepara-
tion: literature research
The two databases used for our literature research were Pubmed 
and ScienceDirect. We limited the search period from the 2000 
to the present. First, an electronic Science Direct search was 
conducted by selecting publications with general keywords: 
“anticancer drug preparations” and “control”; “chemotherapies 
preparations” and “control” in the fields abstract/title/keywords. 
Secondly, we crossed all techniques with “control”. Finally, we 
used specific keywords for each method in order to obtain more 
results: for Raman spectroscopy keywords “Raman spectroscopy” 
and “quality control”; for infrared spectroscopy, “chemotherapies” 
and “infrared”; for gravimetric control, “weight control” and 
“cytotoxic drugs” and for high performance thin layer chroma-
tography, “Chemotherapies” and “High performance thin layer 
chromatography”. All the publications on robotization were found 
on PubMed using a combination of “robotics” and “antineoplastic 
agents”. We also sought data on medication errors linked to anti-
cancer drugs and data on environmental exposure, the former using 
keywords “medication errors” and “antineoplastic agents” and 
the latter, “environmental exposure” and “antineoplastic/adverse 
effects/urine”. Finally, we supplemented our search from legisla-
tive and regulatory sources.
3. Proactive hazard analysis
The entire anticancer care process could be summarized as: 
prescription by physicians, preparation and control by pharmacists 
and administration by nurses. Prescription and administration steps 
were previously analyzed using the FMECA method, so this study 
focused only on the preparation and control steps and not considered 
transport and storage. First, each step in the preparation and control 
process was discussed by a team of pharmacists qualified and 
trained in quality assurance, cytostatic reconstitution and control of 
pharmaceutical preparations. The process was split into 3 steps: step 
1: compounding process; step 2: in-process control; step 3: Prepa-
ration control. We distinguished a process without the analytical 
control step and a process combining a visual in-process control 
followed by an analytical control. All these steps are described in 
Scheme 1. Finally, the production and control phases were divided 
into three parts, as noted in Table  1: conventional preparation in 
an insulator, specific robot items and specific Drugcam® items 
because of the automatic control in real time by the automat.
Table 1: Preparation and control processes for chemotherapies
Step 1 : Compounding process
Conventional preparation in an insulator
Double-control at each stage of preparation
Double-checking during the preparation is carried out by the second preparer:
1. Identification of the different products (active principles, solvents and materials)
2. Patient identification
3. Volumes 
4.  Quantitative validation of the solution in the vial of active principle before and after the addi-
tion in the solvent in comparison with production sheet
Specific robot items
Compounding process  Axis robotics arm and laser-guides work on the gravimetric method 
Specific Drugcam® items
Compounding process
Preparation realized by operator of each stage of the preparation by following the instructions 
on a screen placed nearby that signals the vial errors and sampled volumes including labelling of 
containers in the case of small volume
Step 2 : in process control
Checking of all visual aspects of preparation
Approximate final volume 
Clarity and color of the preparation
Tightness of the preparation
Presence of the clamps on the tube of the diffusers / cassettes / infusion bags
Presence of caps at diffuser ends / syringes / infusion bags
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Scheme 1: Preparation and control process
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Secondly, the same practitioners noted, for each of these steps, 
all potential failure modes envisaged in a process step previously 
determined during brainstorming.
Thirdly, for each potential failure mode, occurrence (O) and severity 
(S) parameters were defined (i.e. risk is defined as a hazard’s 
estimated likelihood of occurrence and the resulting severity of 
consequences). At the same time, the detectability (D) parameter 
was added and represents the ability of the method to detect these 
failure modes before harm is caused. This hazard scoring matrix 
for occurrence, severity of injury and detection (respectively O, S 
and D) was derived from a consensus of the same team of experts 
and was adapted from a study related to proactive risk of errors in 
prescribing and administering drugs (Lago et al. 2012). Five levels 
of occurrence, severity and detectability are described with all 
scores related to these items presented in Table 2.
Table 2: O, S, D score (Lago P et al. 2012)
Occurrence of failure mode (O) Severity of injury (S) Detection by method (D)
1 Remote : less than 
once every 5 years
1 No injury 1 detected 9/10 times
2 Low : once a year to 
once every 5 years
2 Temporary injury 
needing additional 
intervention or 
treatment
2 detected 7/10 times
3 Moderate: one to 
4 a year
3 Temporary injury 
with longer hospital 
stay or increased 
level of care
3 detected 5/10 times
4 High: once a month 4 Permanent effects on 
body functions
4 detected 2/10 times
5 Very high: daily to 
weekly
5 Death or permanent 
loss of major body 
functions
5 detected 0/10 times
Finally, a criticality level was obtained by multiplying the O, S 
and D scores (minimum, 1; maximum, 125). All criticality indexes 
determined for each method are included in a table for analysis of 
the efficiency of the control (production) method(s) in a hospital 
center. The proactive hazard analysis method is described in 
Scheme 2.
4. Results
Thirty-five publications describing the control methods and four-
teen publications on prior risk analysis were obtained. We will first 
discuss the control/production methods integrating robotization 
and then turn to the proactive risk analysis.
4.1. In-process production control, non-analytical 
 methods
4.1.1. Visual control
Visual control is one of the most widely used methods in chemo-
therapy reconstitution units. With its ease of implementation during 
the preparation of cytotoxic drugs, it can be employed during 
each major step of preparation (the production step/compounding 
process and quality control of the finished product). This control 
increases patient safety but is highly dependent on the human 
factor (e.g., work interruption, lack of attention), which may lead 
to a lower quality of the preparation. Different studies evaluated 
advantages and weakness of this method; all these elements are 
described in Table  3 (Bazin et  al. 2015; Bourget et  al. 2012; 
Facchinetti et al. 1999).
4.1.2. Gravimetric control
Gravimetric control is a simple method which compares the 
observed weight of the preparation with its expected weight 
determined by adding the calculated mass of anticancer drugs, 
the mass of the bag and pharmaceutical devices considering the 
density of cytotoxics. The method requires little investment by 
the centralized pharmacy unit, it is fast, universal and widely used 
for the control of anticancer drugs preparations since the 2000s 
(Basuyau et  al. 2000; Le Garlentezec et  al. 2008). Gravimetric 
Step 3 : Preparation control 
Conventional preparation in an insulator: Analytical control method
Preanalytical phase
Validation of the method by a pharmacist 
Calibration of the automaton by a pharmacist and laboratory technicians
Sampling by “unauthorized persons”
Receiving samples in control laboratory
Analytical phase
By the resident in pharmacy or the hospital pharmacist and laboratory technicians
Sample processing
Automaton analysis
Post-analytical phase Results validated by a pharmacist
Specific robot items
Control in-process production Automatic control in real time of key steps of manufacture by the robot
Visual control at the end of the compounding process
Presentation of final product in the loading/unloading chamber and check it by pharmacist.
Printing a final report that resumes every step of preparation
Specific Drugcam® items
Control in-process production Automatic control in real time of key stages of manufacture by the automaton
Visual control at the end of the compounding process Analysis by pharmacist of video control, available from an internet platform
Scheme 2: Risk analysis process
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control presents an important drawback: its lack of specificity. It 
does not allow the identification or quantitation of anticancer drug 
due to their low variability and the lack of knowledge of densities 
(not given in drugs marketing authorizations (AMM) and difficult 
to obtain from pharmaceutical laboratories) (Le Garlantezec et al. 
2008; Delmas et al. 2009; Bazin et al. 2014). Densitometers could 
be used, but this represents an additional and costly investment. 
Confusion is therefore possible between two active principles, 
with serious impacts on patient health. In addition, this type of 
control meets the productivity needs of day hospitals with a limited 
number of preparations per year. It may also suit institutions 
unable to purchase other more expensive methods (Le Garlantezec 
et al. 2008). All criteria related to this technique are discussed in 
Table 3.
4.1.3. Robotization
In recent years, the robot-assisted preparation of chemotherapy 
appeared in centralized unit’s reconstitutions and in the literature 
(Palma et  al. 2012; Chen et al 2013; Nurgat et  al. 2015; Seger 
et  al. 2012). Studies evaluated the qualities of the third genera-
tion APOTECAchemo® and the CytoCare® robots. Criteria 
related to these evaluations are presented in Table 3, considering 
other methods. According to robotization specific criteria, before 
starting the preparation, the robot can recognize all the necessary 
items: drugs, diluent containers and so includes the use of barcodes 
and digital images (Palma et  al. 2012). Confusion between two 
cytotoxics seems unlikely, but the type of bar code used would 
need to be specified to ensure its real reliability. Secondly, all the 
robots operate using a gravimetric method for the control of the 
final product, thereby entailing the previously described disadvan-
tages of this method (Nurgat et al. 2015).
Production time (5 – 20 min) and mechanical limitations are also 
described in the literature. The mechanical limitations concerned 
workflow disruptions (robot downtime); the need to recalibrate the 
device to accept i.v. bags or syringes, medication vials incompat-
ibility and mechanical issues (e.g., robot arm-clamping failures). 
An important production time and a reduction or a discontinuation 
of the activity related to these limitations was not acceptable for 
hospitals (Chen et al. 2013; Nurgat et al. 2015; Yaniv et al. 2013).
Finally, a study of robotic preparation of monoclonal antibodies 
was performed with the robot IV.STATION® in 2013 (Peters et al. 
2014). The results showed that this preparation is feasible for 3 
monoclonal antibodies (bevacizumab, trastuzumab and inflix-
imab) yielding a quality similar to manual compounding. This 
provided the robotic arm to follow the recommendations of the 
SPC (Summary of Product Characteristics). The study should be 
extended to other antibodies used in cancer treatment; the ability to 
control the robot remains a considerable advantage.
4.2. Analytical methods: Control of the fi nished product
4.2.1. High-performance liquid chromatography (HPLC)
HPLC coupled with a UV detector like a Diode Array Detector 
(DAD) is an analytical method widely used (Bazin et  al. 2015; 
Amin et al. 2014; Bourget et al. 2014a; Nussbaumer et al. 2011, 
Paci et al. 2003). This powerful chromatographic method provides 
good results in terms of accuracy and precision in the control of 
monoclonal antibodies (Amin et al 2014; Bourget et al 2014a). 
However, the drawbacks of the technique include in particular 
lengthy analysis time, sampling restrictions, environmental expo-
sure and an important investment cost which limits it use in phar-
macies. All detailed elements are described in Table 4 (Bazin et al. 
2015; Bourget et  al. 2014a; Bourget et  al. 2014b; Delmas et  al. 
2009; Paci et al 2003). In addition, concerning iatrogenesis, HPLC 
is not suited to the intensive production required in day hospi-
tals, which has to be as fast as possible to reduce iatrogenic risk 
(Covinsky et al. 2003; McDonagh et al. 2000; Shojania KG et al. 
2002). HPLC is a technique that requires specialized skills and 
its implementation calls for the continuous training of personnel. 
In terms of compatibility with galenic devices, this method is not 
possible with infusers (physically not possible) and with syringes 
without considering a mother solution, given the problem of 
volume (Bazin et al. 2015).
4.2.2. Flow injection analysis (FIA)
FIA is a method of control that differs from HPLC that there is no 
column (stationary phase) normally allowing compound separation. 
FIA coupled with an UV detector (DAD) allows the identification 
of cytotoxics from direct spectral analysis in a considerably lower 
analysis time (Amin et al. 2014; Bazin et al. 2015). This makes it 
suitable for the speed imposed in reconstitution units. However, 
this method has also been linked to a problem with discrimination/
identification of molecules, in particular ifosfamide/cyclophospha-
mide, doxorubicin/daunorubicin, vindesin/vinblastine. As a result, 
it has to be supplemented with HPLC (Delmas et al. 2009; Nuss-
baumer et al. 2011), a major drawback. Other limitations described 
are in particular the scope (exclusion of monoclonal antibodies), 
the investment cost and the incompatibility with some galenic 
devices (Table 4).
4.2.3. High-performance thin-layer chromatographic 
(HPTLC)
The method is an automatic and accurate version of thin layer 
chromatography. It consists of a silica gel plate with a fluorescent 
indicator coupled with a densitometer to sweep the fluorescent 
zones. Several studies assessed the use of HPTLC for chemo-
Table 3: Non-analytical methods for the control of chemotherapies during production
Control in-process production
Criteria Visual control Gravimetric control Robotization
Accuracy Depends on the preparer No improvementb Sufficient
Human factor High High Low
Risk of occupational exposure to 
cytotoxic
No reduction No reduction Low risk
Traceability Bad Good Good
Professional training Low Low Intermediate
(high in case of failure)
Cost Lowa Low High
References Bazin et al. 2015; Bourget et al. 
2012;
Facchinetti et al. 1999
Basuyau et al. 2000; Bazin et al. 
2015; Bourget et al. 2012; Delmas 
et al 2009; Le Garlantezec et al. 
2008; Lecordier et al. 2011
Palma et al. 2012; Chen et al 2013; Iwamoto 
et al. 2017; Nurgat et al. 2015; Peters et al. 
2014; Schierl et al. 2016; Seger et al. 2012; 
Sessink et al. 2015; Yaniv et al 2013; 
a None study concerning the economic evaluation of this method has already been conducted to the best of our knowledge, but this system requires no instrumentation and seems inexpensive. However, it is 
necessary to take into account the direct personal costs of the member staff and its controller. The lack of a reference time for the preparation may explain the absence of economic studies found in the literature
b small volume preparations (<5 ml)
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therapy production control (Table 4) (Bouligand et al. 2005; Bouli-
gand et al. 2004; Bourget et al. 2001; Bourget et al. 2003; Delmas 
et al. 2009; Gravel et al. 2005; Paci et al. 2003). It is a very inter-
esting technique allowing the control of anticancer drugs as well 
as parenteral nutrition preparations. All the publications from 2001 
to 2005 found in the literature described how HTPLC, introduced 
in the 2000s, can be used routinely. The time required for the result 
is longer than with other methods, i.e. between 12 and 48 hours, 
which is described as an important limitation (Delmas et al. 2009). 
Thus, this technique seems inappropriate for a day hospital unit 
because it requires the chemotherapy to be prepared in advance, 
which is not always possible, depending on the hospital and the 
stability of the anticancer agents.
4.2.4. Fourier transform near infrared spectroscopy 
(FT-NIR) 
Fourier transform near infrared spectroscopy (FT-NIR) is described 
as a fast and easy identification and quantification method of solu-
tions, with a wide scale of detection (Table 4) (Bazin et al. 2015; 
Lê et al. 2014). The main advantage revealed is the non-invasive 
nature of the method since the analysis is performed directly 
through the container. Actually, it is widely reported in the litera-
ture that it is impossible to exclude the risk of cytotoxic exposure 
(Bourget et  al. 2012; Basuyau et  al. 2000; Le Garlantezec et  al. 
2008), with the presence of anticancer agents found in the work 
environment and in particular on the surface of containers, despite 
strict guidelines for safe handling (Buckley et al. 2014). However, 
the major problem with FT-NIR concerns the spectral data of the 
aqueous media dissolving the cytotoxic. This significant problem 
explains the limited use of the method in chemotherapy production 
units, or its systematic combination with other control techniques. 
Finally, this method presents the same limitations as HPLC and 
FIA in terms of compatibility with galenic devices and is efficient 
only for single molecules and diluted preparations (Bazin et  al. 
2015).
4.2.5. UV/visible- IR-FT or Multispec®
Even though Multispec® marketing was stopped in 2011, it 
remains widely used in cytotoxic reconstitution units (Bourget 
et al. 2014a). The Multispec® device combines a UV-visible spec-
trometer with an FT-IR spectrometer allowing both qualitative and 
quantitative analysis of a large number of molecules. The main 
advantage of this device is the extension of the detection spectrum 
to IR, allowing a broader structural analysis than UV-Visible. 
Therefore, it is possible to discriminate molecules such as ifos-
famide and cyclophosphamide or doxorubicin and daunorubicin 
which represented a significant problem before Multispec® (Bazin 
et al. 2010). However, because of the device’s lack of separation 
processes, discrimination of epirubicin and doxorubicin remains 
a problem (Bazin et al. 2014). Another advantage of this method 
is the opportunity that affords for control of monoclonal antibody 
preparations (Bazin et al. 2010). However, it should be recognized 
that Multispec® offers monoclonal antibody preparation control 
with only 35% correct recognition if the spectral library provided 
with the camera used. The development of a new library could 
lead to 100% recognition, but only for 7 monoclonal antibodies 
(Bazin et al. 2010; Bazin et al 2015). All advantages, limitations 
(i.e. sampling volumes, cost…) and criteria evaluated in the litera-
ture are described in Table 4 (Bazin et al. 2014; Bazin et al. 2015; 
Bourget et al. 2014a; Delmas 2009).
4.2.6. Raman Spectrometer: RXN1 analyser® - DXR 
Smart Raman®
Raman spectroscopy is based on the inelastic scattering of a 
photon and is widely used as an analytical tool in many research 
fields. This method involves directing monochromatic light on a 
medium and analyzes the scattered light. Evaluation of this tech-
nique highlighted its strong performance in terms of accuracy and 
precision, although HPLC’s performance remains the strongest 
(Amin et al. 2014; Bourget et al. 2014) in particular for the analyt-
ical control of tablets and capsules (Buckley et al. 2011 Bourget 
et  al. 2003). Other interest like solvent identification (Nardella 
et al. 2016), analysis without sampling, (Amin et al. 2014; Bourget 
et al. 2003, Bourget et al. 2012; Bourget et al. 2014), low volumes 
needed and the possibility of syringes or infusors control have 
been evaluated (Bazin et  al. 2015; Bourget et  al. 2012; Delmas 
et al. 2009). The main drawback here seems to be the necessary 
investment (Bourget et al. 2014). Another, major disadvantage is 
that Raman spectroscopy is an unsuitable control method when 
low concentration infusion bags are involved, due to its lack of 
sensitivity. This considerably limits the use of this tool, as infusion 
bags are used in 90% of preparations.
4.2.7. UV/Raman : QC-Prep®
The QC-Prep® automaton is an example of Raman spectroscopy 
which can be considered as an improved successor to the Multi-
spec® analyser, combining UV and Raman spectrophotometers. 
The interest of this method is related to the alternate use of two 
spectrometers: the UV spectrometer to identify and quantify the 
active substance when it has no Raman spectrum and the Raman 
spectrometer for compounds not identified by UV. We find most 
of the advantages of Raman spectroscopy and in particular the 
facility of this fast method, the identification of solvents, and a 
large scale (Table 4). No improvements have been realized to the 
injector device, already described as inadequate with Multispec®. 
Furthermore, the device’s ease of use has been criticized because 
it requires initial calibration to avoid mistakes (Bazin et al. 2015). 
Moreover, Raman spectroscopy induces lower sensitivity than 
IR because of the loss of the visible spectrum. It can be difficult 
to identify or quantify specific molecules such as monoclonal 
antibodies or eribulin (Bazin et  al. 2015). Like for the Raman 
Spectrometer, the main drawback here seems to be the cost but 
the QC-Prep® may have its place in day hospitals thanks to its 
speed of analysis (less than 2 minutes per sample) (Nardella et al. 
2016).
4.3. Video recording in process and after production
Some hospitals combine video control with other control systems 
in their preparation units. Video recording preparation allows 
both good traceability and the determination of the exact cause 
of a potential non-compliance. Video sequences are archived and 
can be used in a legal framework (Bazin et al. 2015). Although, 
the lack of qualitative and quantitative analysis means that video 
control cannot reliably be used on its own, it is efficient when 
combined with other systems (Table 5).
A new approach to cytotoxic production control was recently 
developed with an intelligent video control system, the DrugCam® 
system. Only one publication described this innovative safety 
approach in two French Hospital Centers (Benizri et  al. 2016). 
In real time, the Drugcam® assist module performs an automatic 
control of production through object recognition (vials, syringes 
and labels). This makes it possible to identify the active principle 
and check syringe volumes. If an error is observed, the production 
process is blocked before the preparation can be dispensed. This 
system has the advantages of visual control but not the drawbacks 
because it eliminates the human factor. Recognition of vials is 
reliable and accurate. This method has been described as an effi-
cient method with a significant specificity and sensitivity with 
small volumes recognition (paediatric formulations) (Benizri et al. 
2016). Similarly, with another module called Drugcam® control, 
it is possible to control preparations after production with video 
recording, which the pharmacist can view during the validation 
step. No system is perfect and the DrugCam® system also has its 
limits. This is not an analytical method, so there is no control of 
the final concentration of the final product. In addition, there is 
no automatic detection of the solvent if they are not previously 
identified by relabelling solvent containers. Furthermore, dark 
colour anticancer drugs like mitoxantrone are difficult to detect. 
Moreover, this system requires significant training of preparers 
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to avoid system crashes at each non-compliance. All details are 
described in Table 5.
Table 5: Analytical methods for control in process and after production
Control in process and after production
Criteria Video control Drugcam®
Analytical target APa + Solvent APa + Solvent
Human factors Yes Yes
Risk of occupational 
exposure to cytotoxic
No risk Yes
Traceability Good Good
Professional training Nothing High
Cost Low cost €45,000 for one work-
station
References Bazin et al. 2015 Benizri et al. 2016
aAP: Active principle
5. Criticality analysis 
For each step in the chemotherapy production and control process, 
the team identified potential risks. 11 failure modes were listed 
during brainstorming: 5 in step 1 and 6 in step 3. As concerns step 
2, the experts identified several risks related to analytical methods: 
errors in method validation, errors in sampling or the degradation 
of reagents ... But these risks do not have a direct impact on the 
patient, apart from delaying medical care, so they were excluded 
from the study. The team did not consider video control anal-
ysis because this method is systematically combined with other 
methods and is of no interest used alone. All risks are described in 
Table 6 with their occurrence and severity.
Error detectability was analyzed for each method of control. A 
criticality level was obtained by multiplying the O, S and D scores; 
results are presented in Table 6. The sum of the criticality indices 
for the different control methods is 74 for visual control, 133 for 
gravimetric control, 54 for robotization, 84 for HPLC, 98 for FIA, 
93 for HTPLC, 79 for UV/Visible-IR-FT, Multispec®, 136 for 
Raman Spectrometry, 79 for UV/Raman, QC-Prep and 95/67 for 
Drugcam® method. The lowest scores were obtained with visual 
control and robotization, the methods showing the lowest criticality 
score being robotization (54) followed closely by Drugcam® (67) 
in the case of the re-labelling of all containers. This is as expected, 
because these methods have recently been developed to reduce the 
risks attributed to preparation of chemotherapies. The two methods 
with the highest criticality score are Raman spectrometry (136) 
and gravimetric control (133), the problem in both cases lying in 
the characteristicsof the antineoplastic agents. Actually, Raman 
spectrometry is not appropriate for the control of chemotherapies 
because many antineoplastic agents do not have a Raman spec-
trum. The problem about gravimetric control it is that a few anti-
neoplastic agents have the same density. These two last methods 
do not reduce most of the identified risks and will not prevent a 
wrong dose. Visual control achieves a good criticality score and 
combined with other methods, it allows additional control, in 
particular for the control of expired products where no method, 
except Drugcam®, is effective. The analytical methods, except for 
Raman spectroscopy, reduce the risk of wrong doses since they are 
based on assay methods. However, only the HPLC method solves 
the problem of the wrong active principle. None of these methods 
makes it possible to check whether the container is right, and only 
the QC-Prep® and the Multispec® checking whether the solvent 
is right. Global analysis of criticality confirmed that no method 
could be considered perfect, including the recently developed 
robotization and Drugcam®. But if two methods are associated 
(analytical and non-analytical) it is possible to reduce the risk or 
bringing it closer to zero. In addition, other promising methods, 
not described here, may be developed for anticancer chemotherapy 
control, LC-MS/MS or capillary electrophoresis with UV detec-
tion for example (Nussbaumer et al. 2010; Guichard et al. 2018). Ta
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Considering hospital priority, the utilization of a combined method 
should implicate a gain in term of personal intervention limitation, 
cost or iatrogenic limitations evidences.
6. Conclusion and perspectives 
This analysis showed that there is a wide range of methods for 
the control of anticancer chemotherapy preparations, and that 
analytical method(s) can be included in the production process. 
To date, no perfect method of control has been developed to 
prevent iatrogenic risk. This proactive hazard analysis may help 
institution’s choosing the right control method which is difficult 
as many parameters have to be considered. While the quality of 
chemotherapies is the primary aim of such controls, environmental 
contamination is becoming equally important. With treatment 
advances in recent years, the control also needs to cover evaluation 
of monoclonal antibodies. Moreover, the time required for control 
should be taken into account, since the longer the time spent in a 
day hospital the greater is the iatrogenic risk. Thus, although not 
obligatory yet, analytical methods for control of chemotherapy 
preparations appear vital, in view of the consequences of produc-
tion errors for patients. However, the cost of an analytical control 
remains an important criterion under current financial constraints. 
Using a combined method should offer a gain in real terms for an 
hospital.
Conflicts of interest: The authors declare that they have no conflict of interest.
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